The Anglo-Scandinavian Cardiovascular Outcomes Trial (ASCOT) was a prospective, randomised, open-label trial with a blinded endpoint and a double-blind 2 × 2 factorial component. ASCOT tested the primary hypothesis that the calcium channel blocker amlodipine (with perindopril as required) would be more effective for preventing coronary heart disease than the β-blocker atenolol (with or without a diuretic). People with hypertension in the UK, Ireland, and Nordic countries (n=19 342) were randomly assigned within blood pressure-lowering arm (BPLA).
Original Article: [Comment] Revisiting ASCOT 16 years later